↓ Skip to main content

Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2

Overview of attention for article published in Clinical Materials, May 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
14 news outlets
blogs
2 blogs
twitter
2 X users
patent
1 patent

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
119 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2
Published in
Clinical Materials, May 2014
DOI 10.1016/j.biomaterials.2014.05.011
Pubmed ID
Authors

Marian H. Hettiaratchi, Tobias Miller, Johnna S. Temenoff, Robert E. Guldberg, Todd C. McDevitt

Abstract

Biomaterials capable of providing localized and sustained presentation of bioactive proteins are critical for effective therapeutic growth factor delivery. However, current biomaterial delivery vehicles commonly suffer from limitations that can result in low retention of growth factors at the site of interest or adversely affect growth factor bioactivity. Heparin, a highly sulfated glycosaminoglycan, is an attractive growth factor delivery vehicle due to its ability to reversibly bind positively charged proteins, provide sustained delivery, and maintain protein bioactivity. This study describes the fabrication and characterization of heparin methacrylamide (HMAm) microparticles for recombinant growth factor delivery. HMAm microparticles were shown to efficiently bind several heparin-binding growth factors (e.g. bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (FGF-2)), including a wide range of BMP-2 concentrations that exceeds the maximum binding capacity of other common growth factor delivery vehicles, such as gelatin. BMP-2 bioactivity was assessed on the basis of alkaline phosphatase (ALP) activity induced in skeletal myoblasts (C2C12). Microparticles loaded with BMP-2 stimulated comparable C2C12 ALP activity to soluble BMP-2 treatment, indicating that BMP-2-loaded microparticles retain bioactivity and potently elicit a functional cell response. In summary, our results suggest that heparin microparticles stably retain large amounts of bioactive BMP-2 for prolonged periods of time, and that presentation of BMP-2 via heparin microparticles can elicit cell responses comparable to soluble BMP-2 treatment. Consequently, heparin microparticles present an effective method of delivering and spatially retaining growth factors that could be used in a variety of systems to enable directed induction of cell fates and tissue regeneration.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Spain 1 <1%
Unknown 116 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 41 34%
Student > Master 14 12%
Researcher 11 9%
Student > Bachelor 10 8%
Professor 5 4%
Other 19 16%
Unknown 19 16%
Readers by discipline Count As %
Engineering 23 19%
Agricultural and Biological Sciences 18 15%
Biochemistry, Genetics and Molecular Biology 12 10%
Materials Science 11 9%
Medicine and Dentistry 11 9%
Other 18 15%
Unknown 26 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 108. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2020.
All research outputs
#387,351
of 25,374,917 outputs
Outputs from Clinical Materials
#59
of 10,751 outputs
Outputs of similar age
#3,283
of 241,294 outputs
Outputs of similar age from Clinical Materials
#1
of 167 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,751 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,294 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 167 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.